Adaltis Inc. Obtains an Order Establishing a Claims Process

MONTREAL, QUEBEC, Jul 13 (MARKET WIRE) --
Adaltis Inc. (TSX: ADS), an international in vitro diagnostic (IVD)
company, today announced that it has obtained an order from the Quebec
Superior Court establishing a claims process for the purpose of
determining the claims of the creditors of Adaltis and for the calling
and conducting of a meeting of the creditors of Adaltis once a plan of
compromise and arrangement has been filed.

In its order, the Court also set to August 13, 2009 the bar date for the
filing of a proof of claim. Creditors who fail to file a claim by such
date will be precluded from any participation in any eventual
distribution.

Such order will allow Adaltis to determine the quantum of claims that
will be subject to any future plan of compromise and arrangement and to
deal with such claims against Adaltis.

Adaltis has been operating under the protection of the Companies'
Creditors Arrangement Act (Canada) since July 3, 2009.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements within the
meaning of applicable Canadian securities legislation. These statements
include those relating to statements that are not historical facts, and
reflect the current intentions, plans, expectations and beliefs of
Adaltis' management. Such forward-looking statements reflect management's
current beliefs and are based on information currently available to
management. Forward-looking statements involve known and unknown risks,
uncertainties and other factors outside of management's control. A number
of factors could cause actual results of Adaltis to differ materially
from the results predicted in the forward-looking statements, including,
but not limited to, risks associated with obtaining regulatory
registrations, affecting our ability to achieve our strategy in China and
other emerging markets, the successful and timely completion of our
ongoing research and development efforts in particular related to
Eclectica(tm), the launch of new products, the uncertainties of market
factors and regulatory processes to which our business is subject, the
ability to recover the value of our holdings of asset-backed commercial
paper following the restructuring of the asset-backed commercial paper
market, and the availability and terms of any financing.

Further, actual results or events could differ materially from those
contemplated in forward-looking statements as a result of the risks and
uncertainties relating to the CCAA proceedings (the "CCAA Proceedings")
including: any negative impacts on the Corporation's business, results of
operations, financial position, cash management arrangements and
limitations on the Corporation's ability to freely deploy its cash
resources throughout the Corporation; relationships with employees,
customers, creditors, suppliers and other stakeholders resulting from the
CCAA Proceedings; the failure of the Corporation to obtain an initial
court order substantially on the terms applied for or to obtain
subsequent court orders extending the applicable stays of action and
proceedings against the Corporation to permit it to propose a
restructuring plan to affected creditors; the sufficient alternative
debtor-in-possession financing during the CCAA Proceedings; the failure
of the Corporation to obtain the requisite approvals of affected
creditors or the court for any restructuring plan, or to successfully
implement such a plan or obtain sufficient exit financing, if required,
within the time granted by the court, which could result in substantially
all of its debt obligations becoming immediately due and payable or
subject to immediate acceleration, leading to the likely liquidation of
the Corporation's assets; that the Corporation's existing common shares
could have no material value in, and following the approval of, a
restructuring plan and could be cancelled; and the potential that the
Toronto Stock Exchange may suspend trading or delist the Corporation's
common shares on or from such stock exchange as a result of the CCAA
Proceedings. For additional information with respect to certain of these
and other factors, refer to our Annual Information Form under the heading
"Risk Factors" filed with the Canadian securities commissions.

The forward-looking statements contained in this news release represent
the expectations of Adaltis and its subsidiaries as at the date hereof
and accordingly are subject to change after such date. However, Adaltis
and its subsidiaries expressly disclaim any intention or obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by
applicable law.

About Adaltis Inc.

Adaltis is an international in vitro diagnostic company with a mission to
become a leading provider of in vitro diagnostic products in emerging
markets, with a particular focus on China.

With the strategic advantage of its "state of the art" reagent
manufacturing facility located in Shanghai, China, a complete IVD product
offering targeting emerging markets, and a strong international sales and
distribution platform, Adaltis is able to manufacture high-quality
products in a low-cost GMP environment, in order to service existing
markets in Europe, while providing a platform to penetrate the
high-growth Chinese in vitro diagnostic market.

Adaltis is headquartered in Montreal, with offices in China, Italy,
Mexico and other parts of the world.

Contacts:
Adaltis Inc.
David Gardner
Executive Vice President and Chief Financial Officer
514-335-9922, ext. 228
david.gardner@adaltis.com

Copyright 2009, Market Wire, All rights reserved.

-0-